Promino Nutritional Sciences Inc. Secures $1.72M in Private Placement Financing

Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) has successfully completed a private placement financing, raising $1.72 million by issuing over 9.5 million units at $0.18 each. This capital infusion will bolster the company's financial stability and growth prospects, as it looks to accelerate sales and fulfillment of its marquee muscle strength and recovery sports beverages, Promino™ and Rejuvenate Muscle™ Health.

The private placement financing, which closed on February 24, 2025, saw significant participation from original investors in the company. The funds raised will be primarily used to re-establish a key intellectual property license and to fund new product for commercialization. This strategic move will enable Promino to strengthen its balance sheet, improve its financial health, and invest in growth initiatives that can drive revenue and market share.

Promino's CEO, Vito Sanzone, expressed gratitude for the investors' support and confidence in the company's vision and growth strategy. "This financing is a testament to the confidence investors have in our products and our ability to execute on our growth strategy. We are grateful for their support and look forward to using these funds to drive our business forward," said Sanzone.

The company's recent milestones, including the re-establishment of a critical intellectual property license and the launch of pre-clinical studies to evaluate Promino's efficacy in cancer patients and muscle retention for those on GLP-1 drugs like Ozempic™, have positioned Promino for continued growth and commercialization success in the coming year. With a strengthened direct-to-consumer (DTC) infrastructure and growing retailer partnerships, Promino is poised for continued revenue growth in late 2024 and into 2025.

Promino's dedication to delivering premium nutritional solutions that address diverse health needs is driving momentum in the marketplace. As the company moves into 2025, it is excited by the opportunities ahead and confident that the foundation it has built will enable it to continue delivering value for its shareholders.

In conclusion, Promino Nutritional Sciences Inc.'s successful private placement financing has strengthened its financial stability and growth prospects. With the raised capital, the company is well-positioned to accelerate sales and fulfillment of its marquee products, settle outstanding liabilities, and invest in general working capital purposes. As Promino continues to execute on its growth strategy, investors can expect to see further progress and value creation from the company.